# Concord Biotech Ltd (CONCORDBIO)
> Exchange: NSE | Sector: Pharma | ISIN: 

## Price
Current Price: ₹1153.3
Day Change: +2.67%
52W High: ₹2150.4
52W Low: ₹987
Market Cap: ₹11,771 Cr

## Valuation
P/E: 37.83
P/B: 6.49
EPS: ₹29.74
Book Value: ₹173.32
Dividend Yield: 0%

## Returns
1Y Return: -23.07%

## Profitability
ROE: 0%
ROCE: 27.2%
Debt/Equity: 0
Revenue Growth: 13.7%
Profit Growth: -16.3%
EBITDA Margin: 37.2%
Operating Margin: 28.89%

## About
Concord Biotech Ltd is a Biotechnology company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Biotechnology
Sub Industry: Unknown

## Business Model
Overview: Concord Biotech Ltd makes money through Technology services, Digital transformation projects, Maintenance and managed services in Biotechnology. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Technology services
- Digital transformation projects
- Maintenance and managed services
Operating Model:
- Wins client contracts, deploys skilled delivery teams, and earns project or recurring service revenue.
- Utilisation, billing rates, attrition, and currency movements are key operating levers.
Recent Context:
- Announcement: Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Announcement: Announcement under Regulation 30 (LODR)-Updates on Acquisition
- BSE Filing: Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

## Access
Current tier: anonymous
More history: Register free to see 3 more years.

## Data Freshness
Quote Updated: 2026-05-24T20:00:07.443Z
Price History Updated: 2026-05-25T05:29:29.719Z
Latest Price History Date: 2026-05-24
Technicals Updated: 2026-05-25T05:29:29.719Z
Quant Updated: 2026-05-25T05:29:29.719Z
Sentiment Updated: 2026-05-25T05:29:29.719Z
Financials Status: current
Financials Updated: 2026-05-18T10:31:25.418Z
Financials Last Attempt: 2026-05-18T10:31:25.418Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (Mar 2021)
Revenue: ₹512 Cr
Operating Profit: ₹205 Cr (OPM 40%)
Net Profit: ₹169 Cr
Tax: ₹214 Cr

## Annual P&L History
Mar 2021: Rev ₹512Cr | PAT ₹169Cr | OPM 40%
Mar 2022: Rev ₹616Cr | PAT ₹235Cr | OPM 53%
Mar 2023: Rev ₹713Cr | PAT ₹175Cr | OPM 38%

## Balance Sheet (Mar 2021)
Total Assets: ₹941 Cr
Total Liabilities: ₹941 Cr
Borrowings: ₹52 Cr
Cash: ₹undefined Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Sudhir Jairam Vaid, Executive Chairman & MD
- Ankur  Vaid, Joint MD, CEO & Executive Director
- Prakash Lalchand Sajnani, Assistant VP of Accounts & Finance
- Raviraj  Kariaas, Chief Financial Officer
- Paritosh  Trivedi, Company Secretary, Compliance Officer & Nodal Officer

---
Source: rupiya.io/stocks/concordbio
Disclaimer: For research and education only. Not investment advice.